Lipocine (LPCN)

• Market cap: $25.5M
• 1 day: 0.85%
• 5 days: -6.11%
• 1 month: -14.39%
• 3 months: 28.30%
• 6 months: -25.27%
• Year to date: 66.43%
• 1 year: 98.33%
• 5 years: -29.90%
• 10 years: -94.71%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

Employees: 17

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

0.19% more ownership

Funds ownership: 9.99% [Q2] → 10.18% (+0.19%) [Q3]

5% less funds holding

Funds holding: 19 [Q2] → 18 (-1) [Q3]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

44% less capital invested

Capital invested by funds: $4.4M [Q2] → $2.44M (-$1.96M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 110% upside
• Avg. target: $10 110% upside
• High target: $10 110% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Alliance Global Partners Scott Henry 33% 1-year accuracy 1 / 3 met price target

110% upside $10

Buy Initiated

24 Sept 2024